Evidence map›Paper›PMID 41630025›Full record

ArticleAnnals of clinical microbiology and antimicrobials2026

Genomic epidemiology and aztreonam-avibactam resistance mechanisms of Proteus mirabilis in china: an eight-year retrospective study.

Jingyi Guo, Chengjin Wu, Xinyan Tang, Linfang Wang, Yan Qi, Yunsong Yu, Yuexing Tu, Linyue Zhang, Xi Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingyi GuoLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Chengjin WuLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Xinyan TangLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Linfang WangLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Yan QiMedical Laboratory Center, Hangzhou TCM Hospital Affiliated to the Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yunsong YuLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Yuexing TuSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. tuyuexing1988@163.com.
Linyue ZhangDepartment of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China. 11718216@zju.edu.cn.
Xi LiLaboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. lixi_0611@163.com.

Funding

the Medical and Health project of Zhejiang Province 2022KY998the National Health Commission Scientific Research Fund-Zhejiang Provincial Major Health Science and Technology Plan Project WKJ-ZJ-2219the National Health Commission Scientific Research Fund-Zhejiang Provincial Major Health Science and Technology Plan Project WKJ-ZJ-2414the National Natural Science Foundation of China 82402665the National Natural Science Foundation of China 82472323the Research and Development Program of Zhejiang Province 2023C03068Zhejiang Provincial Natural Science Foundation Outstanding Youth Program LR25H200001
6 · The paper itself

Abstract

backgroundProteus mirabilis has emerged as an important multidrug-resistant opportunistic pathogen, with the production of metallo-β-lactamases (MBLs) being a major contributor to its broad-spectrum resistance. Although the aztreonam-avibactam (ATM-AVI) combination represents a key therapeutic option against MBL-producing Enterobacteriaceae, the mechanisms underlying ATM-AVI resistance in P. mirabilis has not yet been reported.

methodsA total of 176 multidrug-resistant P. mirabilis isolates were collected from a tertiary hospital in China (2017-2024). Antimicrobial susceptibility testing identified ATM-AVI-resistant isolates (MIC ≥ 8/4 µg/mL). Whole-genome sequencing, gene cloning, RT-qPCR, and copy number analyses were used to determine resistance mechanisms. Growth rate assays evaluated fitness costs, and global phylogenetic analysis elucidated evolutionary and dissemination patterns.

resultsTwelve isolates (6.8%, 12/176) were resistant to ATM-AVI, all carrying the bla

conclusionsThe bla

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamDrug Resistance, Multiple, BacterialProteus InfectionsProteus mirabilisBacterial Proteinsbeta-LactamasesChinaDrug CombinationsGenome, BacterialHumansMicrobial Sensitivity TestsMolecular EpidemiologyPhylogenyRetrospective StudiesAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonamaztreonam, avibactam drug combinationBacterial Proteinsbeta-LactamasesDrug CombinationsAztreonam-avibactam resistancebla PER-4Genomic epidemiologyProteus mirabilis

Identifiers

PMID41630025
PMCPMC12955263

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.